These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Goldstein LB; Amarenco P; Zivin J; Messig M; Altafullah I; Callahan A; Hennerici M; MacLeod MJ; Sillesen H; Zweifler R; Michael K; Welch A; Stroke; 2009 Nov; 40(11):3526-31. PubMed ID: 19745172 [TBL] [Abstract][Full Text] [Related]
43. Atorvastatin and cardiovascular risk in the elderly--patient considerations. Acharjee S; Welty FK Clin Interv Aging; 2008; 3(2):299-314. PubMed ID: 18686752 [TBL] [Abstract][Full Text] [Related]
44. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR; Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710 [TBL] [Abstract][Full Text] [Related]
45. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Schwartz GG; Chaitman BR; Goldberger JJ; Messig M Am Heart J; 2011 May; 161(5):993-9. PubMed ID: 21570534 [TBL] [Abstract][Full Text] [Related]
46. Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Chan KE; Thadhani R; Lazarus JM; Hakim RM Clin J Am Soc Nephrol; 2010 May; 5(5):856-66. PubMed ID: 20338963 [TBL] [Abstract][Full Text] [Related]
47. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Callahan A Am J Cardiol; 2001 Oct; 88(7B):33J-37J. PubMed ID: 11595197 [TBL] [Abstract][Full Text] [Related]
50. C-reactive protein levels and outcomes after statin therapy. Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E; N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109 [TBL] [Abstract][Full Text] [Related]
51. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Corvol JC; Bouzamondo A; Sirol M; Hulot JS; Sanchez P; Lechat P Arch Intern Med; 2003 Mar; 163(6):669-76. PubMed ID: 12639199 [TBL] [Abstract][Full Text] [Related]
52. The collaborative atorvastatin diabetes study: preliminary results. Owen OG Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477 [TBL] [Abstract][Full Text] [Related]
53. Differences between statins on clinical endpoints: a population-based cohort study. Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665 [TBL] [Abstract][Full Text] [Related]
54. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322 [TBL] [Abstract][Full Text] [Related]
55. Effect of statins in stroke prevention. Amarenco P Curr Opin Lipidol; 2005 Dec; 16(6):614-8. PubMed ID: 16276237 [TBL] [Abstract][Full Text] [Related]
56. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Ray KK; Cannon CP Curr Opin Lipidol; 2004 Dec; 15(6):637-43. PubMed ID: 15529022 [TBL] [Abstract][Full Text] [Related]
57. Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. Kashima Y; Izawa A; Aizawa K; Koshikawa M; Kasai H; Tomita T; Kumazaki S; Tsutsui H; Koyama J; Ikeda U J Cardiol; 2009 Aug; 54(1):76-9. PubMed ID: 19632524 [TBL] [Abstract][Full Text] [Related]